If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
== Personal life == Fischer married Agnes Gerlach in 1888. She died seven years later, leaving him a widower with three sons. The younger two died during their military service in World War I, but the oldest, Hermann, became an organic chemist. Fischer died in Berlin on 15 July 1919 at the age of 66. He was Protestant
Afghanistan was formerly the primary producer of the drug. Having regularly producing 70 percent of the world's opium, Afghanistan decreased production to 74 tons per year under a ban by the Taliban in 2000, a move which cut production by 94 percent. A year later, after American and British troops invaded Afghanistan, removed the Taliban and installed the interim government, the land under cultivation leapt back to 285 square miles (740 km2), with Afghanistan supplanting Burma to become the world's largest opium producer once more. Opium production increased rapidly in Afghanistan from that point, reaching an all-time high in 2006. According to DEA statistics, Afghanistan's production of oven-dried opium increased to 1,278 tons in 2002, more than doubled by 2003, and nearly doubled again during 2004. In late 2004, the U.S. government estimated that 206,000 hectares were under poppy cultivation, 4.5 percent of the country's total cropland, and produced 4,200 metric tons of opium, 76 percent of the world's supply, yielding 60 percent of Afghanistan's gross domestic product. In 2006, the UN Office on Drugs and Crime estimated production to have risen 59 percent to 165,000 hectares (407,000 acres) in cultivation, yielding 6,100 tons of opium, 82 percent of the world's supply. The value of the resulting heroin was estimated at US$3.5 billion, of which Afghan farmers were estimated to have received US$700 million in revenue. For farmers, the crop can be up to ten times more profitable than wheat. The price of opium is around US$138 per kilo.
== Main applications == DMG-PEG 2000 has similar chemical properties to the phospholipids that make up the cell membrane. This enables lipid nanoparticles composed of it to easily merge with the cell membrane, delivering its contents.
Sources: en.wikipedia.org
=== Further reading === Ball, S. J. The Cold War: An International History, 1947–1991 (1998). British perspective Beschloss, Michael, and Strobe Talbott. At the Highest Levels:The Inside Story of the End of the Cold War (1993) Braithwaite, Rodric et al. "Could the Soviet Union Have Survived? We ask four historians whether the demise of one of the 20th century's superpowers was as inevitable as it now seems." History Today (Oct 2020) 70#10 pp 8–10 [online]. Brooks, Stephen G., and William C. Wohlforth. "Power, globalization, and the end of the Cold War: Reevaluating a landmark case for ideas." International Security 25.3 (2001): 5-53. [online] Engel, Jeffrey A. When the World Seemed New: George H. W. Bush and the End of the Cold War (2017) Gaddis, John Lewis. The United States and the End of the Cold War: Implications, Reconsiderations, Provocations (1992) online Garthoff, Raymond. The Great Transition: American-Soviet Relations and the End of the Cold War (1994) online Goertz, Gary and Jack S. Levy, eds. Causal explanations, necessary conditions, and case studies: World War I and the End of the Cold War (2005), 10 essays from political scientists; online Hogan, Michael, ed. The End of the Cold War. Its Meaning and Implications (1992) articles from Diplomatic History Kalinovsky, Artemy M. "New Histories of the End of the Cold War and the Late Twentieth Century." Contemporary European History 27.1 (2018): 149–161. online Kegley Jr, Charles W. "How did the Cold War die? Principles for an autopsy." Mershon International Studies Review 38.Supplement_1 (1994): 11–41.
states led by Democratic attorneys general filed a federal lawsuit against the Trump administration and its Department of Health and Human Services, challenging changes to the childhood vaccination schedule that reduced the number of routinely recommended immunisations and shifted some to "shared clinical decision-making". On August 10, 2026, Trump signed an executive order requiring the vaccine for measles, mumps, and rubella to be split into three separate shots, and recommending that "to the maximum extent feasible, all childhood immunizations should be administered at separate medical visits".
=== Winemaking and fungal source chitosan === Chitosan has a long history for use as a fining agent in winemaking. Fungal source chitosan has shown an increase in settling activity, reduction of oxidized polyphenolics in juice and wine, chelation and removal of copper (post-racking) and control of the spoilage yeast Brettanomyces. These products and uses are approved for European use by the EU and OIV standards.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.